Effects of ranitidine bismuth citrate on Helicobacter pylori motility, morphology and survival

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 6, 1999, Pages 753-760

  Worku, M L ^a   Sidebotham, R L ^a   Karim, Q N ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; BISMUTH CITRATE; RANITIDINE; RANITIDINE BISMUTH CITRATE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL MOTILITY; CELL ORGANELLE; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLAGELLUM; HELICOBACTER PYLORI; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-ULCER AGENTS; BISMUTH; HELICOBACTER PYLORI; HUMANS; MICROSCOPY, ELECTRON; ORGANOMETALLIC COMPOUNDS; RANITIDINE;

EID: 0033038439     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00536.x     Document Type: Article

References (49)

1. 1 Hessey SJ, Spencer J, Wyatt JI. et al. Bacterial adhesion and disease in Helicobacter-associated chronic gastritis. Gut 1990; 31: 134-8.
2. 2 Baron JH. The ageing stomach. In: Gasbarrini, Pretolani, eds. Basic and Clinical Aspects of Helicobacter Pylori Springer-Verlag Berlin Heidelberg. 1993: pp. 48-53.
3. 3 O'Connor F, Buckley M, O'Morain C. Helicobacter pylori: the cancer link. J R Soc Med 1996; 89: 674-8.
4. 4 Eaton KA, Morgan DR, Krakowka S. Virulence factors for Campylobacter (Helicobacter) pylori in gnotobiotic piglets. Infect Immunity 1989; 57: 1119-25.
5. 5 Eaton KA, Morgan DR, Krakowka S. Motility of Helicobucter pylori and virulence for gnotobiotic piglets. J Med Microbiol 1992; 37: 123-7.
6. 6 Eaton KA, Morgan DR, Brooks CL, Krakowka S, Essential role of urease in the pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immunity 1991; 59: 2470-5.
7. 7 Karim QN, Ashton L, Sidebotham RL. et al. Measurement of Helicobacter pylori motility in different growth phases in conventional broth cultures by real time computer tracking. J Med Microbiol 1996; 44: x (Abstract).
8. 8 Karim QN, Dhir NK, Logan RPH, Baron JH, Misiewicz JJ. Sidebotham RL. Urcase influences Helicobacter pylori motility at the gastric mucosal surface. Gut 1995; 37(Suppl. 1): 76.(Abstract).
9. 9 Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH. Antibacterial action of bismuth in relation to Campylobacter pyloridis (Helicobacter pylori) colonization and gastritis. Digestion 1987; 37(Suppl. 2): 16-30.
10. 2 blocker resistant duodenal ulcer: role of Helicobacter pylori. Gut 1992; 33: 179-83.
11. 11 Hui W, Lam SK, Ho J, et al. Effects of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci 1991; 36: 577-82.
12. 12 Louw JA, Lucke W, Jasklewicz K, et al. Helicobacter pylori suppression by the proton pump inhibitors: a class effect? S Afr Med J 1993; 83: 784.(Abstract).
13. 13 Sidebotham RL, Batten JJ, Li K, Spencer J, Baron JH. Some effects of tripotassium dicitrato bismuthate on gastric secretion and the mucous barrier. Aliment Pharmacol Ther 1990; 4: 535-46.
14. 14 Lindberg P. Brandstom A, Wallmark B. Structure-activity relationships of omeprazole analogues and their mechanisms of action. Trends Pharmacol Sci 1987; 8: 399-402.
15. 15 Beil W, Bierbaum S, Sewing KF. Studies on the mechanism of action of colloidal bismuth subcitrate. I. Interaction with sulfhydryls. Pharmacol 1993; 47: 135-40.
16. 16 Zech K, Steinijans VW, Huber R, Kolassa N, Radtke HW. Pharmacokinetics and drug interactions x relevant factors for choice of a drug. Int J Clin Pharmacol Ther 1996; 34(Suppl. 1): S3-S6.
17. 17 Sarosiek J, Roche JK, Marshall BJ, McCallum RW. Urcase enzyme inhibition by bismuth subsalicylate. A putative antibacterial mechanism. Gastroenterology 1990; 98: 119.
18. 18 Ottlecz A, Romero JJ, Graham DY, Lichtenberger LM. Inhibitory effect of bismuth salts on Helicobacter pylori phospholipase activity. Gastroenterology 1991; 100: 136.
19. 19 Nagata K, Satoh H, Iwahi, et al. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urcase activity of Helicohacter pylori. Unique action selective for H. Pylori Cells Anlimicrob Agents Chemother 1993; 37: 769-74.
20. 1-ATPase. Pharmacol 1995; 50: 333-7.
21. 21 Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of blood. J Hyg 1938; 38: 732-48.
22. 22 Hobson GS. The Hobson Tracker (Bacteria edn) Manufacturers Literature 1996.
23. 23 Haschemyer RH, Meyers RJ. Negative staining. In: Hayat MA., ed. Principles and Techniques of Electron Microscopy, Vol 2 New York; Van Nostrand Reinhold Company, 1972: pp. 101-43.
24. 24 Marshall BJ, et al. Original isolation of Campylobacter pyloridis (Helicobacter pylori) from human gastric mucosa. Microbios Lett 1984; 25: 83-8.
25. 25 Goodwin CS, McCulloch RK, Armstrong JA, Wee SH. Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (Helicobacter pylori) from the human gastric mucosa J Med Microbiol 1985; 19: 257-67.
26. 26 Tricottet V, et al. Campylobacter-like organisms and surface epithelium abnormalities in active chronic gastrities in humans: an ultrastructural study. Ultrastruct Pathol 1986; 10: 113-22.
27. 27 McColm AA, McLaren A, Klinkert G, et al. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. Aliment Pharmacol Ther 1996; 10: 241-50.
28. 28 Armstrong TA, Wee SH, Goodwin CS, Wilson DH. Response of Campylobacter pyloridis (Helicobacter pylori) to antibiotics, bismuth and an acid-reducing agent in vitro - an ultrastructural study. J Med Microbiol 1987; 24: 343-50.
29. 29 Suerbaum S. Colonizing a hostile environment. Introductory lecture: IX International Workshop on Gastroduodenal Pathology and Helicobacter pylori. Copenhagen. October 15th 1995 [reported in Helicobacter International 1995; Issue; 1: 5].
30. 30 Manson MD, Tedesco P, Berg HC, Harold FM, Van der Drift C. A proton motive force drives bacterial flagella. Proc Natl Acad Sci 1977; 74: 3060-4.
31. 31 Shioi J-I, Matsuura S, Imae Y. Quantitative measurements of proton motive force and motility in Bacillus subtilis J. Bacteriol 1980; 144: 891-7.
32. 32 Packer HL, Harrison DM, Dixon RM, Armitage JP. The effect of pH on the growth and motility of Rhodobarter sphaeroides WS 8 and the nature of the driving force of the flagellar motor. Biochem Biophys Acta 1994; 1188: 101-7.
33. 33 Sachs G, Meyer-Rosberg K, Scott DR. Melchers K. Acid, protons and Helicobacter pylori. Yale J Biol Med 1996; 69: 301-16.
34. 34 Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996; 111: 886-900.
35. 35 Mauche F, Bode G, Malfertheiner P. Identification and characterisation of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993; 88: 1801.
36. 36 Baer W, Koopman H, Wagner S. Effects of substances inhibiting or uncoupling respiratory chain phosphorylation of Helicobacter pylori. Zentralbl Bakteriol 1993; 280: 253-8.
37. 37 Lambert JR, McLean A. Pharmacology of colloidal bismuth subcitrate (De-Nol) and use in non-ulcer dyspepsia. In: Marshall BJ. McCallum RW, Guerrant RL, Mandell GL, eds. Helicobacter Pylori in Peptic Ulceration and Gastritis Boston; Blackwell Scientific Publications., 1991: pp. 201-9.
38. 38 Munoz DJB, Tasman-Jones C, Pybus J. Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus. Gut 1992; 33: 592-6.
39. 39 Nwokolo CU, Lewin JF, Hudson M, Pounder RE. Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology 1992; 102: 163-7.
40. 40 McNulty CAM, Dent J, Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis (Helicobacter pylori) to 11 antimicrobial agents. Antimicrob Agents Chemother 1985; 28; 837-8.
41. 41 Andreasen JJ, Andersen LP. In vitro susceptibility of Campylobacter pyloridis (Helicobacter pylori) to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathol Microbiol Immunol Scand [B] 1987; 95: 147-9.
42. 42 Vogt K, Warrelmann M, Hahn H. The minimum inhibitory concentrations of various bismuth salts against Campylobacter (Helicobacter) pylori. Zentralbl Bakteriol 1989; 271: 104-8.
43. 43 Lambert JR, King RG, Way DJ, Korman MG, Hansky J. Accumulation of bismuth in gastric mucosa after DcNol therapy. Gastroenterology 1989; 96: A284.(Abstract).
44. 44 Williams MP, Hamilton MR, Sercombe JC, Pounder RE. Seven day treatment for Helicobacter pylori infection: Ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. Aliment Pharmacol Ther 1997; 11: 705-10.
45. 45 Cestari R. Ranitidinc bismuth citrate based triple therapy for seven days is more effective than ranitidine bismuth citrate plus clarithromycin for fourteen days in dyspeptic patients with Helicobacter pylori infection. Aliment Pharmacol Ther 1998; 12: 991-6.
46. 46 Van der Wouden EJ, Thijs JC, Van Zwet AA, Kooy A, Kleibeuker JH. One week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidinc bismuth citrate and clarithromycin for Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 1228-31.
47. 47 Goddard A, Logan R. One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995; 7: 1-3.
48. 48 Harris AW, Misiewicz JJ. Eradication of Helicobacter pylori. Bailliere's Clin Gastroenterol 1995; 9: 583-613.
49. 49 Sjostrom JE. Kuhler T, Larsson H. Basis for the selective anti bacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 1997; 41: 1797-801.